newsfilter
← Latest News
GlobeNewswire·

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential